Article info
Extended report
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
- Dr Mark Genovese, Stanford University, Division of Immunology and Rheumatology, 1000 Welch Road #203, Palo Alto, CA, 94304, USA; genovese{at}stanford.edu
Citation
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
Publication history
- Accepted September 8, 2007
- First published October 5, 2007.
Online issue publication
November 02, 2019
Article Versions
- Previous version (2 November 2019).
- Previous version (2 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 BMJ Publishing Group and European League Against Rheumatism